{
    "landscapeName": "Approval Timelines",
    "displayKey": [
      "name",
      "originator_company",
      "drug_class"
    ],
    "iconsKey": [
      "roa",
      "development_status",
      "region"
    ],
    "colorsKey": [
      "moa"
    ],
    "phases": {
      "2016": {
        "priority": 0,
        "assets": [
          {
            "id": "32",
            "brand_name": "Mavenclad",
            "generic_name": "Cladribine",
            "other_name": "",
            "name": "Mavenclad",
            "originator_company": [
              "Merck KGaA"
            ],
            "licensee_company": [
              
            ],
            "moa": [
              "T & B Lymphocytes Suppressant"
            ],
            "drug_class": "Small Molecule",
            "developmentphase_comment": "",
            "other_comments": "<ul><li><p>Mavenclad, a first oral short-course treatment for highly active RMS was approved in EU in Q3 2017, which is followed by regulatory approvals in Canada, Australia, Israel &amp; Argentina. Merck plans additional filings for Mavenclad in other countries, including US.</p></li><li><p>US approval for the drug is anticipated during Q4 2018 to Q2 2019.</p></li></ul>",
            "roa": [
              {
                "position": "top-left",
                "name": "Oral",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/oral.png"
              }
            ],
            "colors": {
              "T & B Lymphocytes Suppressant": "#0c0bac"
            },
            "region": [
              {
                "id": "17",
                "regionId": "3",
                "name": "EU",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/er.png",
                "position": "bottom-bar"
              },
              {
                "id": "47",
                "regionId": "2",
                "name": "Japan",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/jp.png",
                "position": "bottom-bar"
              },
              {
                "id": "16",
                "regionId": "1",
                "name": "USA",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/us.png",
                "position": "bottom-bar"
              }
            ]
          }
        ],
        "color": {
          "background": "#333333",
          "color": "#ffffff"
        }
      },
      "2017": {
        "priority": 0,
        "assets": [
          {
            "id": "32",
            "brand_name": "Mavenclad",
            "generic_name": "Cladribine",
            "other_name": "",
            "name": "Mavenclad",
            "originator_company": [
              "Merck KGaA"
            ],
            "licensee_company": [
              
            ],
            "moa": [
              "T & B Lymphocytes Suppressant"
            ],
            "drug_class": "Small Molecule",
            "developmentphase_comment": "",
            "other_comments": "<ul><li><p>Mavenclad, a first oral short-course treatment for highly active RMS was approved in EU in Q3 2017, which is followed by regulatory approvals in Canada, Australia, Israel &amp; Argentina. Merck plans additional filings for Mavenclad in other countries, including US.</p></li><li><p>US approval for the drug is anticipated during Q4 2018 to Q2 2019.</p></li></ul>",
            "roa": [
              {
                "position": "top-right",
                "name": "Oral",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/oral.png"
              }
            ],
            "colors": {
              "T & B Lymphocytes Suppressant": "#0c0bac"
            },
            "region": [
              {
                "id": "1",
                "regionId": "3",
                "name": "EU",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/er.png",
                "position": "bottom-bar"
              }
            ]
          },
          {
            "id": "41",
            "brand_name": "Ocrevus",
            "generic_name": "ocrelizumab",
            "other_name": "",
            "name": "Ocrevus",
            "originator_company": [
              "Biogen"
            ],
            "licensee_company": [
              "Roche"
            ],
            "moa": [
              "Anti-CD20 Antibody"
            ],
            "drug_class": "Biologic",
            "developmentphase_comment": "",
            "other_comments": "<ul><li><p>On 12 Jan'18, Ocrevus received EU approval for treatment of patients with RRMS &amp; PPMS. Approval was based on data from 3 pivotal Phase III studies from ORCHESTRA trial programme of 2,388 patients who met primary and nearly all key secondary endpoints. (<a href=\"https://www.roche.com/media/store/releases/med-cor-2018-01-12.htm\" target=\"_blank\">Roche January 12, 2018 PR</a>)</p></li></ul>",
            "roa": [
              {
                "position": "top-right",
                "name": "IV",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/iv.png"
              }
            ],
            "colors": {
              "Anti-CD20 Antibody": "#c13c50"
            },
            "region": [
              {
                "id": "16",
                "regionId": "1",
                "name": "USA",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/us.png",
                "position": "bottom-bar"
              }
            ]
          }
        ],
        "color": {
          "background": "#333333",
          "color": "#ffffff"
        }
      },
      "2018": {
        "priority": 0,
        "assets": [
          {
            "id": "41",
            "brand_name": "Ocrevus",
            "generic_name": "ocrelizumab",
            "other_name": "",
            "name": "Ocrevus",
            "originator_company": [
              "Biogen"
            ],
            "licensee_company": [
              "Roche"
            ],
            "moa": [
              "Anti-CD20 Antibody"
            ],
            "drug_class": "Biologic",
            "developmentphase_comment": "",
            "other_comments": "<ul><li><p>On 12 Jan'18, Ocrevus received EU approval for treatment of patients with RRMS &amp; PPMS. Approval was based on data from 3 pivotal Phase III studies from ORCHESTRA trial programme of 2,388 patients who met primary and nearly all key secondary endpoints. (<a href=\"https://www.roche.com/media/store/releases/med-cor-2018-01-12.htm\" target=\"_blank\">Roche January 12, 2018 PR</a>)</p></li></ul>",
            "roa": [
              {
                "position": "top-right",
                "name": "IV",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/iv.png"
              }
            ],
            "colors": {
              "Anti-CD20 Antibody": "#c13c50"
            },
            "region": [
              {
                "id": "17",
                "regionId": "3",
                "name": "EU",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/er.png",
                "position": "bottom-bar"
              }
            ]
          },
          {
            "id": "32",
            "brand_name": "Mavenclad",
            "generic_name": "Cladribine",
            "other_name": "",
            "name": "Mavenclad",
            "originator_company": [
              "Merck KGaA"
            ],
            "licensee_company": [
              
            ],
            "moa": [
              "T & B Lymphocytes Suppressant"
            ],
            "drug_class": "Small Molecule",
            "developmentphase_comment": "",
            "other_comments": "<ul><li><p>Mavenclad, a first oral short-course treatment for highly active RMS was approved in EU in Q3 2017, which is followed by regulatory approvals in Canada, Australia, Israel &amp; Argentina. Merck plans additional filings for Mavenclad in other countries, including US.</p></li><li><p>US approval for the drug is anticipated during Q4 2018 to Q2 2019.</p></li></ul>",
            "roa": [
              {
                "position": "top-right",
                "name": "Oral",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/oral.png"
              }
            ],
            "colors": {
              "T & B Lymphocytes Suppressant": "#0c0bac"
            },
            "region": [
              {
                "id": "1",
                "regionId": "3",
                "name": "EUe",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/er.png",
                "position": "bottom-bar"
              }
            ]
          },
          {
            "id": "41",
            "brand_name": "Ocrevus",
            "generic_name": "ocrelizumab",
            "other_name": "",
            "name": "Ocrevus",
            "originator_company": [
              "Biogen"
            ],
            "licensee_company": [
              "Roche"
            ],
            "moa": [
              "Anti-CD20 Antibody"
            ],
            "drug_class": "Biologic",
            "developmentphase_comment": "",
            "other_comments": "<ul><li><p>On 12 Jan'18, Ocrevus received EU approval for treatment of patients with RRMS &amp; PPMS. Approval was based on data from 3 pivotal Phase III studies from ORCHESTRA trial programme of 2,388 patients who met primary and nearly all key secondary endpoints. (<a href=\"https://www.roche.com/media/store/releases/med-cor-2018-01-12.htm\" target=\"_blank\">Roche January 12, 2018 PR</a>)</p></li></ul>",
            "roa": [
              {
                "position": "top-right",
                "name": "IV",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/iv.png"
              }
            ],
            "colors": {
              "Anti-CD20 Antibody": "#c13c50"
            },
            "region": [
              {
                "id": "16",
                "regionId": "1",
                "name": "USAa",
                "iconPath": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/us.png",
                "position": "bottom-bar"
              }
            ]
          }
        ],
        "color": {
          "background": "#333333",
          "color": "#ffffff"
        }
      }
    },
    "legends": {
      "colors": {
        "T & B Lymphocytes Suppressant": "#0c0bac",
        "Anti-CD20 Antibody": "#c13c50"
      },
      "icons": {
        "addClass@@Oral": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/oral.png",
        "flagClass@@Japan": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/jp.png",
        "flagClass@@EU": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/er.png",
        "addClass@@IV": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/iv.png",
        "flagClass@@USA": "genzyme-staging.integratedge.com/assets/452e696b/images/genzyme/us.png"
      }
    },
    "subfilters": {
      "180": "Anti-CD20 Antibody",
      "226": "T & B Lymphocytes Suppressant"
    },
    "productType": "marketed",
    "viewMode": "year"
  }